Clinical Trials Logo

Recurrent/Post-Chemotherapy WHO Grade II Glioma clinical trials

View clinical trials related to Recurrent/Post-Chemotherapy WHO Grade II Glioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01678352 Recruiting - Clinical trials for Recurrent/Post-Chemotherapy WHO Grade II Glioma

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

Start date: October 2012
Phase: Phase 0
Study type: Interventional

This is a pilot study of a vaccination regime that is designed to efficiently induce anti-tumor T-cell responses in patients with WHO grade II glioma. The proposed regime with BTIC Lysate in combination with imiquimod, an FDA-approved immune response modifier will induce potent anti-glioma immune response with minimal or no toxicity.